Cita APA (7a ed.)
Jauslin, P., Kulkarni, P., Li, H., Vatakuti, S., Hussain, A., Wenning, L., & Kerbusch, T. (2019). Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis. Clinical Pharmacokinetics, 58(8), 1059-1069.
Cita Chicago Style (17a ed.)
Jauslin, Petra, Pooja Kulkarni, Hanbin Li, Suresh Vatakuti, Azher Hussain, Larissa Wenning, y Thomas Kerbusch. "Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis." Clinical Pharmacokinetics 58, no. 8 (2019): 1059-1069.
Cita MLA (9a ed.)
Jauslin, Petra, et al. "Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis." Clinical Pharmacokinetics, vol. 58, no. 8, 2019, pp. 1059-1069.
Precaución: Estas citas no son 100% exactas.